Summary The concentrations of glutathione S-transferase (GST) B, and B2 (Alpha), Pi and Mu have been measured by radioimmunoassay in cytosols from 28 oestrogen receptor (ER) rich and 30 ER-poor breast tumours. GST B1, B2 and Pi was detected in all 58 breast tumour cytosols whilst GST Mu was found in only 28. Of the GSTs, Pi was expressed most strongly in all cytosols and the concentration was significantly higher in ER-poor tumour cytosols than in ER-rich tumours (P<0.01). As with GST Pi, the highest levels of GST The glutathione S-transferases (GST) are a family of dimeric enzymes which are found in the cell cytoplasm. They have been implicated in the detoxification of a wide range of xenobiotics and chemotherapeutic agents (Jakoby, 1978; Mannervik, 1985; Buller et al., 1987) . Three immunologically distinct major classes of GST occur in humans Alpha (that comprises B, and B2 subunits), Mu and Pi (Mannervik et al., 1985; Stockman et al., 1985) . Although present in most human cells, the expression of the various GST isoenzymes may vary between different types of tissue (Strange et al., 1984) . Approximately half the population do not express GST Mu and appear more susceptible to developing lung cancer if they smoke heavily (Seidegard et al., 1986) . GST Pi has been associated with pre-neoplastic and neoplastic change and may be present in many human tumours and cell lines (Ilio et al., 1986; Kodate et al., 1986; Shiratori et al., 1987; Shea et al., 1988; Mannervik et al., 1987) .
The glutathione S-transferases (GST) are a family of dimeric enzymes which are found in the cell cytoplasm. They have been implicated in the detoxification of a wide range of xenobiotics and chemotherapeutic agents (Jakoby, 1978; Mannervik, 1985; Buller et al., 1987) . Three immunologically distinct major classes of GST occur in humans Alpha (that comprises B, and B2 subunits), Mu and Pi Stockman et al., 1985) . Although present in most human cells, the expression of the various GST isoenzymes may vary between different types of tissue (Strange et al., 1984) . Approximately half the population do not express GST Mu and appear more susceptible to developing lung cancer if they smoke heavily (Seidegard et al., 1986) . GST Pi has been associated with pre-neoplastic and neoplastic change and may be present in many human tumours and cell lines (Ilio et al., 1986; Kodate et al., 1986; Shiratori et al., 1987; Shea et al., 1988; Mannervik et al., 1987) .
Using a cDNA probe, over-expression of GST Pi RNA has been found in a multidrug-resistant cell line of breast cancer and also in a small series of 21 breast cancers (Moscow et al., 1988) . In the same study an inverse correlation was found between expression of GST Pi and the oestrogen receptor levels in the tumour. The expression of the Alpha and Mu classes of GST was not measured.
In the present study we have used specific radioimmunoassays to measure the expression, at the protein level, of GST Pi, Mu, B, and B2 in cytosols from a larger group of 58 breast cancers.
Methods

Patients
Fifty-eight women with histologically proven invasive breast cancer were studied. Apart from four patients (three treated with tamoxifen and one with chemotherapy), none had received prior therapy for their malignancy.
Tumour was obtained from the primary cancer in 53 cases and from an axillary lymph node invaded with cancer in the remaining five individuals. The tumours were transported on ice to a cold room and then stored in liquid nitrogen until assayed. (Hawkins et al., 1981) . Tumour cytosol was incubated overnight at 4°C with 3H-17 P-oestradiol. Separation of free and bound steroid was by addition of dextran-coated charcoal; the bound fraction was measured by liquid scintillation counting. Concentration of receptors was determined by Scatchard analysis (Scatchard, 1949) . Activities below 20 pmol mg-' cytosol protein were designated oestrogen receptor poor (ER-poor) and those with activities in excess of 20 pmol mg-' cytosol protein as ERrich.
Cytosol preparation
Measurement of GST concentrations
Specific radioimmunoassays, described in detail previously (Beckett & Hayes, 1984; Hussey et al., 1987; Howie et al., 1988) , were used to determine the concentration of GST Pi, GST Mu, GST B1 and GST B2 isoenzymes in the 58 breast cytosols. The standards used for the B1, B2 and Mu assays were purified from human liver obtained from transplant donors and for GST Pi from fresh human placenta.
The cytosol, if required, was diluted in assay diluent consisting of 25 mmol 1' sodium phosphate buffer pH 7.6 bovine serum albumin (1 g 1') and sodium azide (0.2 g 1-l) before analysis. Within-assay coefficients of variation of less than 10% was achieved in all assays.
Protein measurement
The dye binding technique described by Bradford (1976) , adapted for use on a Cobas Fara (Roche Diagnostic Ltd, Welwyn Garden City, UK) centrifugal analyser was used for total protein estimation.
Results
The median levels of each of the GST isoenzymes in the breast cytosols are shown in Table I . GST Pi, B, and B2 were detected in all breast tumour cytosols, whereas GST Mu was found in only 28 (48%) of the 58 cytosols. GST For GST Mu, data is given for only the 28 tumours that expressed the protein.
concentrations ranged from 0.6 to 48 ltg g-' cytosolic protein and 0.04 to 5.3 fig g-' cytosolic protein, respectively ( Figure   1 ). The levels of B, and B2 were positively correlated (r = 0.66, P<0.001) but GST Pi did not correlate with the expression of other GST.
The concentrations of GST in the cytosols subdivided according to the ER status as shown in Figure 1 . Levels of GST Pi were significantly higher in ER-poor tumours (P<0.01, Mann-Whitney U test). Indeed, the tumours with the 11 highest GST Pi values were in the ER-poor tumours.
As with GST Pi, the highest levels of GST B1 and GST B2
were observed in ER-poor tumours with the eight highest 
GST Bt
tern of GST expression between groups was observed if a level of <5 pmol mg-' was used to define ER status.
There was no relationship between levels of GSTs and the age or menopausal status of the patients from whom the tumour was derived. Furthermore, no obvious association was apparent between GST and lymph node involvement or tumour T stage in the subgroup of patients in whom this information was available. Similarly, there was no indication that tumour cellularity, central necrosis or a special histological type was associated with increased expression of GSTs.
The frequency with which GST Mu was expressed in the breast cancers was not significantly different from the frequency of expression of GST Mu found using lymphocytes obtained from a group of 42 laboratory volunteers where 23 (55%) volunteers expressed the enzyme (test of confidence limits for a proportion; Snedecor & Cochran, 1974) .
Discussion
Our results concerning the elevated expression of GST Pi in ER-poor breast cancer are compatible with the data of Moscow et al. (1988) , who showed increased mRNA levels for GST Pi in a similar group of tumours. This suggests that raised mRNA levels in ER-poor tumours results in an increased production of GST Pi protein. In addition, we have shown that both B, and B2 GST appear to be over-expressed in some ER-poor tumours.
Although the role of GST Pi in conferring drug resistance has been recently questioned (Yusa et al., 1988) an association between GST Pi expression and acquisition of drug resistance has been widely reported (for review see Hayes & Wolf, 1988) . It has been suggested that the increased levels of GST Pi in ER-poor tumours will confer a poorer prognosis because such patients will have a lesser chance of responding to chemotherapeutic agents (Moscow et al., 1988) . However, it should be noted that ER-poor tumours often have a high proliferation rate (Meyer et al., 1977) and this can be associated with rapid response to chemotherapy (Stoll, 1986) . Additionally, there is no consensus on whether response rates to chemotherapy differ significantly in ER-rich and ER-poor tumours (Hawkins et al., 1980; Carle et al., 1984) . In rat mammary tumours increases in the Alpha class GST are also associated with resistance to chemotherapeutic agents (Buller et al., 1987) . In our study 11 ER-poor tumours overexpressed GST Pi while six and four ER-poor tumour overexpressed GST B, and GST B2, respectively. However, we have no clinical evidence that these increased Alpha class and Pi class GST levels are associated with chemotherapeutic insensitivity. Aquisition of multi drug resistance in MCF-7 breast cancer cells is associated not only with an increase in GST Pi expression but also with a loss of hormone sensitivity. Our data show that both GST Pi and Alpha class GST expression is inversely linked to ER status. These observations are of interest since ER-poor tumours as a group are associated with worse prognosis than those which are ER-rich (McGuire et al., 1975a; Nicolson et al., 1981; Hawkins et al., 1987; Courdi et al., 1988) . Whether this results from ER-rich cancers being inherently more indolent or more likely to respond to steroid hormone deprivation therapy is not clear (Howell et al., 1984; Saez et al., 1983; Adami et al., 1985) . However, it also has to be emphasised that whereas ER-poor tumours rarely respond to hormone manipulation (McGuire et al., 1975b; Le Clerq & Heuson, 1977) , the present results showed that only a small proportion of ER-poor tumours have elevated levels of GST. In this respect the observation that ER-negative breast cancers can be divided into subgroups on the basis of other tumour characteristics such as epidermal growth factor receptors, vimentin and p53 expression is relevant (Cattoretti et al., 1988) . In the case of EGF receptors, this may be of prognostic value (Sainsbury et al., 1987) but it is not known if there is an association between GST Pi expression and EGF receptor levels. It will be of interest to know whether patients having tumour with overexpression of GST will return more quickly with recurrent disease than those with lower GST, irrespective of ER status.
GST Pi maps to chromosome 11 (Moscow et al., 1988 ), which has an increased incidence of deletions in ER-poor tumour cells when compared to ER-rich tumours (Ali et al., 1987) . These observations have led to the suggestion of a link between over-expression of GST Pi and a specific deletion on chromosome 11. The Alpha class of GST, however, map to chromosome 6 (Board & Webb, 1987) and we have shown that both GST B, and GST B2 are also over-expressed in some ER-poor tumours. These data suggest that there may be a common mechanism, rather than specific chromosomal deletions, that leads to over-expression of the GST in certain breast cancers.
The incidence of GST Mu expression in both the ER-rich and ER-poor breast tumours was not significantly different from the incidence of GST Mu expression found in lymphocytes from the normal population (Seidegard et al., 1986; Hussey et al., 1987) . This suggests a lack of association between expression of GST Mu and breast cancer.
In summary, glutathione S-transferases B,, B2 and Pi have been found in all cytosols of breast cancer whereas Mu was detected in only about one-half. High levels of GST B,, B2 and Pi were limited to ER-poor tumours, the clinical significance of which merits further study.
